Keyword: Vasant Narasimhan
The Zolgensma data integrity crisis wiped out the "building trust with society" part of Vas Narasimahan's annual bonus in 2019.
Novartis' Sandostatin has been on the U.S. market for 20 years, but it's tough to produce—and that has the drugmaker predicting a generics-free 2020.
Novartis hopes to remove a clinical hold on the high dose of an intrathecal form of Zolgensma but expects a filing based just on the lower doses.
If you couldn’t be on the ground at this year’s J.P. Morgan conference, never fear—we’ve compiled all the zingers you missed throughout the week.
After another scandal in 2019, Novartis is taking its pledge to build trust with society a step further.
Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.
Thanks to Novartis' MedCo buyout pact, PCSK9 competition is about to get more intense. But can it really make its heart prospect work?
Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.
Zolgensma hauled in $160 million in its first full quarter on the market, more than 60% above the Street's expectations.
Big Pharma CEOs have their own way of cozying up to the world’s second largest pharmaceutical market—by getting themselves Chinese names.